Vir Biotechnology, Inc. (VIR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.39-0.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — achieve at least 45% revenue growth in FY2026: FY26 revenue estimate $245.3M (0% revisions up, 4 down in 30d) vs 45% growth target.
Vir Biotechnology has strong clinical progress with positive Phase 2 data enhancing product potential. The company has partnerships supporting its growth strategy. Analysts expect about 46% revenue growth next year. The stock trades at a significant discount to peers, reflecting potential upside if the turnaround succeeds.
Vir is loss-making with a recent earnings miss and negative EPS trends. Key executives have departed, raising concerns about management stability. Revenue estimates decline after 2026, and the company faces elevated risk with no clear profitability timeline.
The market prices in about 46% revenue growth next year and reflects elevated risk with the stock trading roughly 56% below our valuation level. Our view aligns with consensus revenue growth but recognizes the company remains unprofitable and speculative.
Breaks if: negative clinical trial results or delays in 2026
Breaks if: EPS loss worsens beyond -0.81 next quarter
revenue growth falls below ~45% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is focused on advancing its drug development programs, but it faces challenges such as recent earnings misses and management transitions.
The current valuation suggests that the market views VIR as relatively cheap compared to its peers. However, there is a slight expectations gap, indicating that investors are anticipating some level of performance improvement.
VIR has shown strong recent financial performance, but there is an elevated risk of missing earnings expectations in the near term. Management is making progress on key drug development initiatives, but the mixed status of some programs adds uncertainty.
The long-term thesis hinges on the successful advancement of its prostate cancer and hepatitis delta programs, as well as broader sector performance. Key triggers include guidance changes and the impact of economic conditions on the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. This miss raises concerns about the company's ability to achieve revenue growth targets.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, VIR's trajectory will depend on its ability to execute on its development plans and navigate market challenges. Not investment advice.